Highlights • PD-L1≥1% is an independent positive prognostic biomarker in metastatic melanoma • PD-L1≥1% did not derive additional benefit from anti-CTLA-4 over anti-PD-1 alone • Combination therapy demonstrated improved PFS only in patients with PD-L1<1% Abstract Metastatic melanoma (MM) is commonly treated with a combination of nivolumab and ipilimumab, regardless of tumor PD-L1 expression.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Eva
Contact Eva, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack